FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.
What happened
FDA reviewed the website https://www.fitrxapp.com in December 2025 and found it offers compounded semaglutide and tirzepatide drugs — compounded meaning mixed by a pharmacy rather than made as an FDA-approved product. Labels pictured on the site show "FitRx," which tells buyers FitRx made the drugs, when it did not. The site also named the active ingredients in Wegovy, Ozempic, Zepbound and Mounjaro, which FDA says implies the compounded products are FDA-approved when they are not.
What FDA found
The labels pictured on the website carry the name "FitRx," which represents that FitRx made the drugs, but it is not the maker.
FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR 201.1(h)(2)Advertising and promotion of the compounded drugs is false or misleading, which makes the drugs misbranded.
FDCA § 502(bb) [21 U.S.C. § 352(bb)]Website claims naming the active ingredients in Wegovy, Ozempic, Zepbound and Mounjaro imply the compounded products were FDA-approved or checked for safety and effectiveness when they were not.
FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Sending these misbranded drugs across state lines is a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving, delivering or offering to deliver misbranded drugs is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, FitRx must send a written response to the Office of Compounding Quality and Compliance describing the steps taken to fix the violations and prevent them from recurring. The response should identify the entities that make the compounded products, include a sample of the labeling, and explain or correct the other website claims that could be seen as false or misleading.
Who should pay attention
- telehealth and online platforms selling compounded GLP-1 drugs
- marketers and websites that list compounded drugs under their own brand name
- pharmacies and compounders whose products are sold under another company's label
This is a summary. Read the original letter on fda.gov.